Xconomy National

Archives

by in

Entry	Author	Date	Location
Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs	Luke Timmerman	10/27/11	San Francisco
Kineta Adds $2.8M Grant	Luke Timmerman	08/16/11	Seattle
Adaptive TCR, a Fred Hutch Spinoff, Snags $5.8M to Take Immune System Profiling Up a Notch	Luke Timmerman	06/06/11	Seattle
Alder Steers Next Antibodies To Unusual Places: Treating Migraines and High Cholesterol	Luke Timmerman	03/02/11	Seattle
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science	Luke Timmerman	01/06/11	Boston
The Immunex Alumni: Where Are They Now?	Luke Timmerman	01/03/11	Seattle
Adaptive TCR Seeks to Dominate New Industry in Profiling The Immune System	Luke Timmerman	12/13/10	Seattle
Allozyne’s Next Drug, Made to Kill Two Birds With One Stone, Being Prepped for Clinic	Luke Timmerman	11/16/10	Seattle
Resolve Therapeutics, UW Spinoff With an Eye on Lupus, Crafts Recession-Era Business Plan	Luke Timmerman	11/10/10	Seattle
Ambit Biosciences Seeks $86M IPO as Market Warms Up	Luke Timmerman	11/08/10	San Diego
ZymoGenetics CEO Doug Williams Exits the Stage, Mulls Next Free Agent Move	Luke Timmerman	11/08/10	Seattle
Hyperion Nails Pivotal Trial, ChemoCentryx Aims High Against Crohn’s, Vivus Shot Down by FDA, & More Bay Area Life Sciences News	Luke Timmerman	11/05/10	San Francisco
ChemoCentryx, Pursuing the Dream For Autoimmune Disease, Seeks to Put a Pill in a Bottle	Luke Timmerman	11/04/10	San Francisco
ATyr Pharma Pockets $23M to Create New Class of Protein Drugs, and New Targets	Luke Timmerman	10/26/10	San Diego
CalciMedica Charges Ahead Toward First Human Test of Oral Pill for Psoriasis	Luke Timmerman	10/20/10	San Diego
Cytomx, Backed by Third Rock & Roche, Raises $30M for New Class of Antibodies	Luke Timmerman	09/23/10	San Francisco
Lycera CEO Resigns After Less Than One Year, Michigan Startup Plans to Keep Boston Presence	Luke Timmerman	09/17/10	Detroit
Nodality Nears Market With Technology to Get the Right Cancer Drug to the Right Patients	Luke Timmerman	09/16/10	San Francisco
Santarus Adds Two Drugs	Luke Timmerman	09/13/10	San Diego
Nuon Adds $10M Debt, Options	Luke Timmerman	08/12/10	San Francisco
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline	Luke Timmerman	07/14/10	Seattle
Tolera Therapeutics, Cleveland Clinic Spinoff Focused on Immune Disorders, Raises $4M	Luke Timmerman	06/04/10	Detroit
Alder, Bristol Arthritis Drug Shows “Outstanding” Results in Trial, Lead Researcher Says	Luke Timmerman	05/17/10	Seattle
Alder Seeks to Treat Cancer in a Radical Way, Fighting Inflammation, Not Tumors	Luke Timmerman	05/13/10	Seattle
Taligen Adds Maraganore to Board	Luke Timmerman	04/15/10	Boston
Kineta Nabs $600K NIH Grant	Luke Timmerman	04/05/10	Seattle
Adaptive TCR, a Fred Hutch Spinoff, Nabs $4.5M to Uncover Immune System Secrets	Luke Timmerman	03/26/10	Seattle
Innovation Northwest Wrapup: Alder, Tekmira, Acucela, & Other Emerging Little Biotechs	Luke Timmerman	03/19/10	Seattle
Ligand Drug OK’d in Europe	Luke Timmerman	03/12/10	San Diego
Tolerx, After a Decade and $150M, Eagerly Awaits Data from Big Diabetes Trial	Luke Timmerman	03/04/10	Boston
Page 1 of 3	next page »